-
1 Comment
Aier Eye Hospital Group Co., Ltd is currently in a long term uptrend where the price is trading 18.2% above its 200 day moving average.
From a valuation standpoint, the stock is 151.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 24.2.
Aier Eye Hospital Group Co., Ltd's total revenue rose by 47.6% to $4B since the same quarter in the previous year.
Its net income has increased by 62.3% to $870M since the same quarter in the previous year.
Finally, its free cash flow grew by 157.0% to $2B since the same quarter in the previous year.
Based on the above factors, Aier Eye Hospital Group Co., Ltd gets an overall score of 4/5.
| Industry | Medical Care Facilities |
|---|---|
| Sector | Healthcare |
| Exchange | SHE |
| CurrencyCode | CNY |
| ISIN | CNE100000GR6 |
| Market Cap | 99B |
|---|---|
| PE Ratio | 29.39 |
| Beta | 0.55 |
| Target Price | 14.268 |
| Dividend Yield | 1.7% |
Aier Eye Hospital Group Co., Ltd. operates as an ophthalmic medical company in China, Hong Kong, Europe, the United States, Europe, and Southeast Asia. It offers diagnosis and treatment of various ophthalmic diseases, surgical services, medical optometry, and lens fitting for fundus diseases, glaucoma, and cataract. The company also provides training courses for cataract cases, ICL surgery, and presbyopia surgery. Aier Eye Hospital Group Co., Ltd. was founded in 2002 and is headquartered in Changsha, China
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300015.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
